HC Wainwright Has Positive Outlook for BioNTech Q1 Earnings

BioNTech SE (NASDAQ:BNTX) – Equities research analysts at HC Wainwright lifted their Q1 2025 EPS estimates for shares of BioNTech in a report issued on Tuesday, April 1st. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($2.34) for the quarter, up from their prior forecast of ($3.42). HC Wainwright currently has a “Buy” rating and a $145.00 target price on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q2 2025 earnings at ($2.52) EPS, Q3 2025 earnings at ($1.23) EPS, Q4 2025 earnings at $0.58 EPS and FY2025 earnings at ($5.51) EPS.

Other equities analysts have also recently issued reports about the stock. Wells Fargo & Company assumed coverage on shares of BioNTech in a research report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 price objective for the company. Morgan Stanley decreased their price target on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 11th. Citigroup assumed coverage on shares of BioNTech in a research report on Thursday, March 13th. They set a “buy” rating and a $145.00 price objective for the company. Truist Financial began coverage on BioNTech in a research report on Friday, January 10th. They issued a “buy” rating and a $172.00 target price on the stock. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $171.44 price target on shares of BioNTech in a report on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $143.44.

BioNTech Stock Down 4.3 %

BNTX stock opened at $88.05 on Friday. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The business’s 50 day simple moving average is $108.81 and its 200 day simple moving average is $112.88. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $21.13 billion, a PE ratio of -41.93 and a beta of 1.07.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter in the previous year, the business earned $1.90 earnings per share. The business’s revenue was down 19.5% compared to the same quarter last year.

Institutional Investors Weigh In On BioNTech

Several institutional investors and hedge funds have recently bought and sold shares of the company. Jones Financial Companies Lllp increased its holdings in BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after buying an additional 246 shares during the period. Quintet Private Bank Europe S.A. boosted its position in shares of BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after acquiring an additional 700 shares in the last quarter. Allianz SE bought a new position in BioNTech in the fourth quarter valued at approximately $90,000. GAMMA Investing LLC raised its position in BioNTech by 48.2% during the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after purchasing an additional 300 shares in the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. bought a new stake in BioNTech during the fourth quarter worth $137,000. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.